Filing Flows › Fulgent Genetics (FLGT) › Q3 2026
Fulgent Genetics (FLGT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Fulgent Genetics (FLGT) reported revenue of $90.4M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +6% from the quarter before. Operating margin was -24.9%, net loss $13.3M (14.8% of revenue).
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $90.4M | +6% | +8% |
| Operating profit | −$22.5M | — | — |
| Net earnings | −$13.3M | — | — |
| Operating cash flow | $109M | — | +883% |
| Free cash flow | $107M | — | 21× |
What changed
Revenue was $90.4M in Q3 2026, up 8% year over year and up 6% from the previous quarter.
Gross margin was 35.3%, down 6.9 points from Q3 2025. Operating costs exceeded revenue by $22.5M, an operating margin of -24.9%. Operating expenses grew 7% against revenue growth of 8%. The fastest-growing cost line was Sales & marketing (+34%). The quarter ended with a net loss of $13.3M, narrower than the previous quarter's $29.7M loss. Minority interests bore $187K of it: to shareholders the quarter was a loss of $13.2M. Non-operating items added $8.5M, -61% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $109.2M (up 883% year over year). Non-cash charges added back $6.8M of depreciation and amortization and $8.1M of share-based compensation. Working capital and other items added $107.6M. Capital expenditures of $1.8M left free cash flow of $107.4M.
Questions
What was Fulgent Genetics' revenue in the third quarter 2026?
Fulgent Genetics (FLGT) reported revenue of $90.4M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +6% from the quarter before.
Was Fulgent Genetics profitable in the third quarter 2026?
Operating loss was $22.5M (-24.9% of revenue) and net loss $13.3M.
Source: Fulgent Genetics 10-Q on SEC EDGAR.